AstraZeneca and insitro Agree on AI Drug Discovery Partnership
AstraZeneca will pay $40 million upfront, while insitro may receive milestone payments and royalties as they pursue liver and heart treatments.
Key takeaways
- AstraZeneca will pay insitro $40 million upfront under the multi-year deal.
- The partnership will target MASH and cardiomyopathies using insitro’s AI platform.
AstraZeneca will pay biotech company insitro $40 million upfront in a multi-year partnership to seek treatments for liver and heart conditions. Insitro may also receive up to about $1.46 billion in development and commercial milestones, plus a single-digit percentage of future sales in royalties.
The work will focus on metabolic dysfunction-associated steatohepatitis, or MASH, and cardiomyopathies. Insitro will use its “Virtual Human” platform, which combines lab-grown cell models and machine learning, to study disease biology and advance targets selected by AstraZeneca.
AstraZeneca will run and fund any future clinical trials. As of Thursday afternoon, AstraZeneca shares traded at 12,628 GBp, up 2.67% since the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.
